EMA Recommends Extension of Indications for Durvalumab to Include Treatment of Patients with Resectable NSCLC at High Risk of Recurrence By Ogkologos - March 28, 2025 673 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns neoadjuvant and adjuvant treatment of patients with resectable non-small cell lung cancer Source RELATED ARTICLESMORE FROM AUTHOR European Parliament Adopts Its Position on the Critical Medicines Act, Strengthening Security of Cancer Care in Europe ESMO Raises Key Issues on Cancer Prevention and Care at the WHO Executive Board Meeting Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer MOST POPULAR FDA Approves Bosutinib for Paediatric Patients with Chronic Myelogenous Leukaemia October 13, 2023 Peace May 19, 2021 Extended Anticoagulation with Reduced-Dose Non-inferior to Full-Dose Apixaban for the Prevention... April 29, 2025 New Study Shows Intermittent Fasting May Reduce Breast Cancer Risk and... January 26, 2021 Load more HOT NEWS ΜΥΘΟΙ ΚΑΙ ΑΛΗΘΕΙΕΣ Good News and Cautions about Pregnancy for Childhood Cancer Survivors Repurposing radiotherapy drugs could give immunotherapy a boost 177Lu-PSMA-617 Prolongs rPFS Relative to Androgen Receptor Pathway Inhibitor Change, with...
